Robert Abouassaly, MD

Robert Abouassaly, MD

Cleveland Clinic

Cleveland, Ohio

Dr. Abouassaly is an Associate Professor of Urology at the Cleveland Clinic in Cleveland, Ohio. He received his medical degree from the McGill University Faculty of Medicine in Montreal, Canada, in 2002. Dr. Abouassaly then went on to complete residencies in Surgery and Urology at the Cleveland Clinic, followed by a Fellowship in Urologic Oncology at the University of Toronto Faculty of Medicine. He specializes in urology and has published widely about such urologic subjects as nephrectomy, prostate biopsy, and laparoscopic and robotic procedures. In addition to the Cleveland Clinic, Dr. Abouassaly is affiliated with University Hospitals Cleveland Medical Center and University Hospitals Richmond Medical Center.

Disclosures:

Articles by Robert Abouassaly, MD

An Overview of MRI Guided Biopsies for Prostate Cancer

Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.” 

Read More

Can the DECIPHER Marker Predict Chemotherapy?

Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.” 

Read More

Join the GRU Community

- Why Join? -